Could a prostate cancer imaging agent help spot aggressive breast cancer?

NCT ID NCT06586047

Recruiting now Diagnosis Sponsor: Ahmad Shariftabrizi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This early-phase study is testing whether a special PET scan tracer, originally used for prostate cancer, can detect metastatic triple negative breast cancer. Thirty women with advanced disease will receive both standard FDG PET and the new PSMA PET scan. The goal is to see if PSMA shows up on tumors, which could later allow for targeted treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18 F-DCFPyL (a radioactive tracer for PET imaging)
What this could lead to: If successful, this imaging method could identify patients who might benefit from PSMA-targeted therapies, offering a new treatment path for triple negative breast cancer.
What could go wrong: This is a very early, small study (30 people) focused on imaging, not treatment. It may not show enough PSMA activity to justify future therapy trials, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

University of Iowa Healthcare
RECRUITING

Iowa City, Iowa, 52242, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.